Cargando…

Translating imaging traits of mass-forming intrahepatic cholangiocarcinoma into the clinic: From prognostic to therapeutic insights

BACKGROUND & AIMS: The progress toward clinical translation of imaging biomarkers for mass-forming intrahepatic cholangiocarcinoma (MICC) is slower than anticipated. Questions remain on the biologic behaviour underlying imaging traits. We developed and validated imaging-based prognostic systems...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Gu-Wei, Xu, Qing, Jiao, Chen-Yu, Lu, Ming, Xu, Zheng-Gang, Zhang, Biao, Yang, Yue, Wang, Ke, Li, Xiang-Cheng, Wang, Xue-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468367/
https://www.ncbi.nlm.nih.gov/pubmed/37663120
http://dx.doi.org/10.1016/j.jhepr.2023.100839
_version_ 1785099224208113664
author Ji, Gu-Wei
Xu, Qing
Jiao, Chen-Yu
Lu, Ming
Xu, Zheng-Gang
Zhang, Biao
Yang, Yue
Wang, Ke
Li, Xiang-Cheng
Wang, Xue-Hao
author_facet Ji, Gu-Wei
Xu, Qing
Jiao, Chen-Yu
Lu, Ming
Xu, Zheng-Gang
Zhang, Biao
Yang, Yue
Wang, Ke
Li, Xiang-Cheng
Wang, Xue-Hao
author_sort Ji, Gu-Wei
collection PubMed
description BACKGROUND & AIMS: The progress toward clinical translation of imaging biomarkers for mass-forming intrahepatic cholangiocarcinoma (MICC) is slower than anticipated. Questions remain on the biologic behaviour underlying imaging traits. We developed and validated imaging-based prognostic systems for resected MICCs with an appraisal of the tumour immune microenvironment (TIME) underpinning patient-specific imaging traits. METHODS: Between January 2009 and December 2019, a total of 322 patients who underwent dynamic computed tomography/magnetic resonance imaging and curative-intent resection for MICC at three hepatobiliary institutions were retrospectively recruited, divided into training (n = 193) and validation (n = 129) datasets. Two radiological and clinical scoring (RACS) systems, one integrating preoperative variables and one integrating preoperative and postoperative variables, were developed using Cox regression analysis. We then prospectively analysed the TIME of tissue samples from 20 patients who met study criteria from January 2021 to December 2021 using multiplexed immunofluorescence. RESULTS: Preoperative and postoperative MICC-RACS systems built on carbohydrate antigen 19-9, albumin, tumour number, radiological/pathological nodal status, pathological necrosis, and three radiological traits (arterial enhancement pattern, tumour boundary, and capsular retraction) demonstrated good performance in predicting disease-specific (C-statistic >0.80) and disease-free (C-statistic >0.75) survival that outperformed rival models and staging systems across study cohorts (P <0.05 for all). Patients with MICC-RACS score of 0–2 (low risk), 3–5 (medium risk), and ≥6 (high risk) had incrementally worse prognosis after surgery. Significant differences in spatial distribution and infiltration level of immune cells were identified between arterial enhancement patterns. Enhanced infiltration of immunosuppressive regulatory T cells and M2-like macrophages at the invasive margin were noted in tumours with distinct boundary and capsular retraction, respectively. CONCLUSIONS: Our MICC-RACS systems are simple but powerful prognostic tools that may facilitate the understanding of spatially distinct TIMEs and patient-tailored immunotherapy approach. IMPACT AND IMPLICATIONS: The progress toward clinical translation of imaging biomarkers for mass-forming intrahepatic cholangiocarcinoma (MICC) is slower than anticipated. Questions remain on the biologic behaviour of MICC underlying imaging traits. In this study, we proposed novel and easy-to-use tools, built on radiological and clinical features, that demonstrated good performance in predicting the prognosis either before or after surgery and outperformed rival models/systems across major imaging modalities. The characteristic radiological traits integrated into prognostic systems (arterial enhancement pattern, tumour boundary, and capsular retraction) were highly correlated with heterogeneous tumour-immune microenvironments, thereby renovating treatment paradigms for this difficult-to-treat disease.
format Online
Article
Text
id pubmed-10468367
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104683672023-09-01 Translating imaging traits of mass-forming intrahepatic cholangiocarcinoma into the clinic: From prognostic to therapeutic insights Ji, Gu-Wei Xu, Qing Jiao, Chen-Yu Lu, Ming Xu, Zheng-Gang Zhang, Biao Yang, Yue Wang, Ke Li, Xiang-Cheng Wang, Xue-Hao JHEP Rep Research Article BACKGROUND & AIMS: The progress toward clinical translation of imaging biomarkers for mass-forming intrahepatic cholangiocarcinoma (MICC) is slower than anticipated. Questions remain on the biologic behaviour underlying imaging traits. We developed and validated imaging-based prognostic systems for resected MICCs with an appraisal of the tumour immune microenvironment (TIME) underpinning patient-specific imaging traits. METHODS: Between January 2009 and December 2019, a total of 322 patients who underwent dynamic computed tomography/magnetic resonance imaging and curative-intent resection for MICC at three hepatobiliary institutions were retrospectively recruited, divided into training (n = 193) and validation (n = 129) datasets. Two radiological and clinical scoring (RACS) systems, one integrating preoperative variables and one integrating preoperative and postoperative variables, were developed using Cox regression analysis. We then prospectively analysed the TIME of tissue samples from 20 patients who met study criteria from January 2021 to December 2021 using multiplexed immunofluorescence. RESULTS: Preoperative and postoperative MICC-RACS systems built on carbohydrate antigen 19-9, albumin, tumour number, radiological/pathological nodal status, pathological necrosis, and three radiological traits (arterial enhancement pattern, tumour boundary, and capsular retraction) demonstrated good performance in predicting disease-specific (C-statistic >0.80) and disease-free (C-statistic >0.75) survival that outperformed rival models and staging systems across study cohorts (P <0.05 for all). Patients with MICC-RACS score of 0–2 (low risk), 3–5 (medium risk), and ≥6 (high risk) had incrementally worse prognosis after surgery. Significant differences in spatial distribution and infiltration level of immune cells were identified between arterial enhancement patterns. Enhanced infiltration of immunosuppressive regulatory T cells and M2-like macrophages at the invasive margin were noted in tumours with distinct boundary and capsular retraction, respectively. CONCLUSIONS: Our MICC-RACS systems are simple but powerful prognostic tools that may facilitate the understanding of spatially distinct TIMEs and patient-tailored immunotherapy approach. IMPACT AND IMPLICATIONS: The progress toward clinical translation of imaging biomarkers for mass-forming intrahepatic cholangiocarcinoma (MICC) is slower than anticipated. Questions remain on the biologic behaviour of MICC underlying imaging traits. In this study, we proposed novel and easy-to-use tools, built on radiological and clinical features, that demonstrated good performance in predicting the prognosis either before or after surgery and outperformed rival models/systems across major imaging modalities. The characteristic radiological traits integrated into prognostic systems (arterial enhancement pattern, tumour boundary, and capsular retraction) were highly correlated with heterogeneous tumour-immune microenvironments, thereby renovating treatment paradigms for this difficult-to-treat disease. Elsevier 2023-07-04 /pmc/articles/PMC10468367/ /pubmed/37663120 http://dx.doi.org/10.1016/j.jhepr.2023.100839 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Ji, Gu-Wei
Xu, Qing
Jiao, Chen-Yu
Lu, Ming
Xu, Zheng-Gang
Zhang, Biao
Yang, Yue
Wang, Ke
Li, Xiang-Cheng
Wang, Xue-Hao
Translating imaging traits of mass-forming intrahepatic cholangiocarcinoma into the clinic: From prognostic to therapeutic insights
title Translating imaging traits of mass-forming intrahepatic cholangiocarcinoma into the clinic: From prognostic to therapeutic insights
title_full Translating imaging traits of mass-forming intrahepatic cholangiocarcinoma into the clinic: From prognostic to therapeutic insights
title_fullStr Translating imaging traits of mass-forming intrahepatic cholangiocarcinoma into the clinic: From prognostic to therapeutic insights
title_full_unstemmed Translating imaging traits of mass-forming intrahepatic cholangiocarcinoma into the clinic: From prognostic to therapeutic insights
title_short Translating imaging traits of mass-forming intrahepatic cholangiocarcinoma into the clinic: From prognostic to therapeutic insights
title_sort translating imaging traits of mass-forming intrahepatic cholangiocarcinoma into the clinic: from prognostic to therapeutic insights
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468367/
https://www.ncbi.nlm.nih.gov/pubmed/37663120
http://dx.doi.org/10.1016/j.jhepr.2023.100839
work_keys_str_mv AT jiguwei translatingimagingtraitsofmassformingintrahepaticcholangiocarcinomaintotheclinicfromprognostictotherapeuticinsights
AT xuqing translatingimagingtraitsofmassformingintrahepaticcholangiocarcinomaintotheclinicfromprognostictotherapeuticinsights
AT jiaochenyu translatingimagingtraitsofmassformingintrahepaticcholangiocarcinomaintotheclinicfromprognostictotherapeuticinsights
AT luming translatingimagingtraitsofmassformingintrahepaticcholangiocarcinomaintotheclinicfromprognostictotherapeuticinsights
AT xuzhenggang translatingimagingtraitsofmassformingintrahepaticcholangiocarcinomaintotheclinicfromprognostictotherapeuticinsights
AT zhangbiao translatingimagingtraitsofmassformingintrahepaticcholangiocarcinomaintotheclinicfromprognostictotherapeuticinsights
AT yangyue translatingimagingtraitsofmassformingintrahepaticcholangiocarcinomaintotheclinicfromprognostictotherapeuticinsights
AT wangke translatingimagingtraitsofmassformingintrahepaticcholangiocarcinomaintotheclinicfromprognostictotherapeuticinsights
AT lixiangcheng translatingimagingtraitsofmassformingintrahepaticcholangiocarcinomaintotheclinicfromprognostictotherapeuticinsights
AT wangxuehao translatingimagingtraitsofmassformingintrahepaticcholangiocarcinomaintotheclinicfromprognostictotherapeuticinsights